Published on

Medicine – Haemophilia B (Christmas Disease)

Haemophilia B, also known as Christmas disease, is an inherited bleeding disorder caused by deficiency or dysfunction of coagulation factor IX (FIX).

It is clinically almost indistinguishable from haemophilia A, which is caused by factor VIII deficiency.

Important Clinical Principle

Haemophilia B causes defective secondary haemostasis, leading to recurrent joint bleeding, deep muscle haematomas and prolonged bleeding following trauma or surgery.

1. Aetiology and Genetics

  • Deficient factor: Factor IX.
  • Gene: F9 gene on the X chromosome (Xq27).
  • Inheritance: X-linked recessive.
  • Affected individuals: Predominantly males, although females may also have symptomatic haemophilia.
  • Alternative name: Christmas disease.
  • Frequency: Less common than haemophilia A.

The name Christmas disease originated from the surname of the first patient described with this condition.

2. Pathophysiology

Factor IX is a vitamin K-dependent coagulation factor involved in the intrinsic coagulation pathway.

Activated factor IX (FIXa), together with activated factor VIII (FVIIIa), forms the intrinsic tenase complex, which activates factor X.

Factor IX deficiency therefore reduces factor X activation, thrombin generation and fibrin clot formation.

Illustration: Pathophysiology of Haemophilia B

Factor IX Deficiency Haemophilia B Reduced Intrinsic Tenase Activity FIXa–FVIIIa complex impaired Reduced Factor X Activation Reduced Thrombin Generation Impaired Fibrin Clot Formation Unstable haemostasis Deep Tissue and Joint Bleeding

3. Clinical Features

Haemophilia B behaves clinically like haemophilia A. Bleeding severity is closely related to residual factor IX activity.

A. Joint Bleeding (Haemarthrosis)

  • Commonly affects the knees, ankles and elbows.
  • Causes joint pain, swelling, warmth and reduced movement.
  • Repeated haemarthroses may result in chronic haemophilic arthropathy.

B. Deep Muscle Bleeding

  • Muscle haematomas.
  • Iliopsoas haemorrhage.
  • Possible nerve compression and compartment syndrome.

C. Other Bleeding Manifestations

  • Prolonged bleeding following trauma.
  • Excessive bleeding after surgery or dental extraction.
  • Spontaneous bleeding in severe disease.
  • Intracranial haemorrhage, a potentially life-threatening complication.
Examination Point: Haemophilia typically produces deep tissue bleeding and haemarthroses, whereas platelet disorders and von Willebrand disease more commonly produce mucocutaneous bleeding, petechiae and superficial bruising.

4. Classification According to Severity

Severity Factor IX Activity Clinical Presentation
Severe <1% Frequent spontaneous joint and muscle bleeding
Moderate 1–5% Bleeding after minor trauma; occasional spontaneous bleeding
Mild >5% to <40% Bleeding mainly after significant trauma, surgery or procedures

Severity is classified according to baseline factor IX activity, although bleeding patterns may vary between patients.

5. Laboratory Findings

Investigation Typical Result
Prothrombin time (PT)Normal
Activated partial thromboplastin time (aPTT)Often prolonged
Thrombin time (TT)Normal
Platelet countNormal
FibrinogenNormal
Factor IX activityReduced
Factor VIII activityUsually normal
Important Clarification: Mild haemophilia B may have a normal aPTT. A specific factor IX activity assay is required to confirm the diagnosis.

6. Diagnosis

  1. Clinical history of recurrent joint or deep tissue bleeding.
  2. Family history suggestive of X-linked inheritance.
  3. Coagulation screening tests, particularly PT and aPTT.
  4. Specific factor IX activity assay to confirm the deficiency and determine severity.
  5. Genetic testing of the F9 gene when indicated.

A mixing study may help distinguish factor deficiency from a coagulation inhibitor when the aPTT is prolonged.

Diagnostic Flowchart

Suspected Haemophilia Haemarthrosis / deep bleeding Coagulation Screening PT normal; aPTT often prolonged Specific Factor Assays Measure factor VIII and IX activity Reduced Factor IX Activity Factor VIII usually normal Haemophilia B Confirmed Classify severity and plan treatment

7. Treatment of Haemophilia B

A. Factor IX Replacement

Factor IX concentrate is a principal treatment for haemophilia B.

It is used for acute bleeding, perioperative haemostatic cover and prophylaxis.

Extended-half-life factor IX products may reduce the frequency of prophylactic infusions.

B. Prophylaxis

Regular prophylaxis is recommended for many patients with severe haemophilia to prevent recurrent joint bleeding and long-term arthropathy.

C. Additional Management

  • Tranexamic acid for selected mucosal bleeding episodes.
  • Physiotherapy and joint protection.
  • Avoidance of unnecessary intramuscular injections.
  • Avoidance of medications that impair platelet function unless specifically indicated.
  • Specialist management of factor IX inhibitors if they develop.
  • Gene therapy or other newer therapies may be considered in selected patients according to eligibility and local availability.
Important: Desmopressin (DDAVP) is not effective in haemophilia B because it increases factor VIII and VWF release rather than replacing factor IX.

8. Haemophilia A Versus Haemophilia B

Feature Haemophilia A Haemophilia B
Deficient factorFactor VIIIFactor IX
Alternative nameClassical haemophiliaChristmas disease
InheritanceX-linked recessiveX-linked recessive
Clinical featuresJoint and muscle bleedingJoint and muscle bleeding
PTNormalNormal
aPTTOften prolongedOften prolonged
Platelet countNormalNormal
Specific diagnosisReduced factor VIII activityReduced factor IX activity
Main replacement therapyFactor VIIIFactor IX
DDAVPMay help selected mild casesIneffective

9. High-Yield Examination Summary

Aspect Important Point
Alternative nameChristmas disease
Deficient factorFactor IX
GeneF9 gene on X chromosome
InheritanceX-linked recessive
PathophysiologyImpaired intrinsic tenase activity and reduced thrombin generation
Clinical presentationHaemarthrosis, muscle haematomas and prolonged bleeding
PTNormal
aPTTOften prolonged
DiagnosisReduced factor IX activity
TreatmentFactor IX replacement and prophylaxis when indicated

10. Key Examination Pearls

  • Haemophilia B is also known as Christmas disease.
  • It results from factor IX deficiency.
  • It is inherited in an X-linked recessive pattern.
  • Factor IX is a vitamin K-dependent coagulation factor.
  • Haemophilia B is clinically similar to haemophilia A.
  • Haemarthrosis and deep muscle bleeding are characteristic manifestations.
  • PT and platelet count are normal, while aPTT is often prolonged.
  • Mild disease may have a normal aPTT.
  • Diagnosis is confirmed by reduced factor IX activity.
  • Treatment primarily involves factor IX replacement.
  • Desmopressin is ineffective in haemophilia B.
Most Important Examination Point

Haemophilia A and B have virtually identical clinical presentations and routine coagulation screening patterns. They are distinguished by specific factor assays: factor VIII deficiency in haemophilia A and factor IX deficiency in haemophilia B.

Clinical Note

Suspected serious bleeding, particularly intracranial, neck, abdominal or iliopsoas haemorrhage, requires urgent haemophilia specialist assessment and prompt haemostatic treatment. Management must be individualised according to disease severity, inhibitor status and available therapies.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments